17.87
前日終値:
$18.40
開ける:
$18.3
24時間の取引高:
2.70M
Relative Volume:
1.36
時価総額:
$2.86B
収益:
$1.27M
当期純損益:
$-508.02M
株価収益率:
-6.2034
EPS:
-2.8807
ネットキャッシュフロー:
$-419.23M
1週間 パフォーマンス:
-4.28%
1か月 パフォーマンス:
-12.32%
6か月 パフォーマンス:
-17.57%
1年 パフォーマンス:
+9.56%
Denali Therapeutics Inc Stock (DNLI) Company Profile
名前
Denali Therapeutics Inc
セクター
電話
(650) 866-8547
住所
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
DNLI
Denali Therapeutics Inc
|
17.87 | 2.86B | 1.27M | -508.02M | -419.23M | -2.8807 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-13 | 再開されました | JP Morgan | Overweight |
| 2026-03-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Peer Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-04-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2025-01-07 | 開始されました | Robert W. Baird | Outperform |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-12-16 | アップグレード | Stifel | Hold → Buy |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 開始されました | B. Riley Securities | Buy |
| 2023-01-30 | 開始されました | SVB Securities | Outperform |
| 2022-12-05 | 開始されました | Cowen | Outperform |
| 2022-11-02 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-02 | 開始されました | BofA Securities | Buy |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-09-21 | 開始されました | Oppenheimer | Outperform |
| 2021-09-01 | 開始されました | SMBC Nikko | Outperform |
| 2021-05-18 | 開始されました | UBS | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-08-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-13 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-02-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-02-24 | 開始されました | Jefferies | Buy |
| 2020-02-19 | 開始されました | Stifel | Hold |
| 2020-01-27 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-26 | 開始されました | Wedbush | Neutral |
| 2019-09-13 | 開始されました | Nomura | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-11-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 開始されました | Janney | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | 開始されました | Goldman | Neutral |
| 2018-01-02 | 開始されました | JP Morgan | Overweight |
| 2018-01-02 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Denali Therapeutics Inc (DNLI) 最新ニュース
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
Alector, Inc. (ALEC) Stock Price, News, Quote & History - Yahoo Finance
Denali Therapeutics (DNLI) Stock Looks Stretched On Fair Value Yet Reasonable On Book Value - simplywall.st
The Technical Signals Behind (DNLI) That Institutions Follow - Stock Traders Daily
Denali at Cantor global healthcare conference: launch gains traction By Investing.com - Investing.com India
Denali at Cantor global healthcare conference: launch gains traction By Investing.com - Investing.com UK
Denali Therapeutics (DNLI) Institutional Ownership 2026 $DNLI - MarketBeat
Denali Therapeutics Insider Transactions: Officer Peter Scott Chin to Sell 1,654 Shares, Director Nancy Thornberry Sells 11,439 Shares (NASDAQ: DNLI) - kalkinemedia.com
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com UK
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com South Africa
Denali Therapeutics director sells $261,928 in stock - Investing.com
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com Canada
Denali Therapeutics director sells $261,928 in stock By Investing.com - Investing.com Nigeria
Denali Therapeutics director sells $261,928 in stock - Investing.com
Denali Therapeutics (NASDAQ: DNLI) holder to sell shares to cover tax on stock units - Stock Titan
Denali Therapeutics Director Nancy Thornberry Executes Two Stock Sales Under Rule 10b5-1 Plan - kalkinemedia.com
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing - marketscreener.com
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing - Yahoo Finance
Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale - Stock Titan
Denali Therapeutics (NASDAQ: DNLI) exec plans 2,768-share Rule 144 sale - stocktitan.net
Denali (DNLI) Session: Finishes 2.89% Lower at $24.20; Technical View: Price Remains Between $22.99 Support and $25.41 ResistanceOBV Trend Line - vinanet.vn
Denali Therapeutics (DNLI) Stock Dropped, So Why Is It Drawing Fresh Attention? - sahmcapital.com
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - AOL.com
145,045 Shares in Denali Therapeutics Inc. $DNLI Purchased by Great Lakes Advisors LLC - MarketBeat
Denali’s DNL921 Trial: Early Alzheimer’s Safety Data That Could Shape Long-Term Upside - TipRanks
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? - TradingView
Edmond DE Rothschild Holding S.A. Invests $4.25 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali (DNLI) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Market Reaction: Shares Finish 3.25% UpDividend Increase Stocks - vinanet.vn
Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha
Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report - Sahm
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund - Kalkine Media
Denali Therapeutics Inc.: Fundamental Analysis and Financial Ratings | DNLI | US24823R1059 - marketscreener.com
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock - MarketBeat
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One (NASDAQ:DNLI) - Seeking Alpha
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout - ChartMill
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Equities Analysts Set Expectations for DNLI Q3 Earnings - MarketBeat
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) holder to sell 2,857 restricted shares via broker - Stock Titan
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June R - GuruFocus
Weekly Recap: Q2 revenue, big net loss and DNL126 Phase 3 with 2027 BLA - TradingView
Denali climbs past Avlayah expectations with $3.6M in revenue - BioSpace
(DNLI) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42 - Moomoo
Denali Therapeutics Inc (DNLI) 財務データ
収益
当期純利益
現金流量
EPS
Denali Therapeutics Inc (DNLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chin Peter Scott | Officer |
Sep 04 '26 |
Proposed Sale |
22.29 |
1,654 |
36,867 |
0 |
| Thornberry Nancy | Director |
Sep 02 '26 |
Sale |
22.90 |
11,439 |
261,929 |
19,686 |
| NANCY THORNBERRY | Director |
Sep 02 '26 |
Proposed Sale |
23.27 |
11,439 |
266,128 |
0 |
| Schuth Alexander O. | COFO and Secretary |
Sep 01 '26 |
Sale |
23.44 |
2,768 |
64,882 |
278,995 |
| ALEXANDER SCHUTH | Officer |
Sep 01 '26 |
Proposed Sale |
23.76 |
2,768 |
65,768 |
0 |
| Schuth Alexander O. | COFO and Secretary |
Aug 11 '26 |
Sale |
25.07 |
2,857 |
71,625 |
281,763 |
| Schuth Alexander O. | Officer |
Aug 11 '26 |
Proposed Sale |
25.07 |
2,857 |
71,624 |
0 |
| CAROLE HO | Former Affiliate |
Feb 05 '26 |
Proposed Sale |
20.29 |
39,490 |
801,394 |
0 |
| CAROLE HO | Former Affiliate |
Feb 04 '26 |
Proposed Sale |
21.18 |
150,000 |
3,176,970 |
0 |
| CAROLE HO | Former Affiliate |
Feb 03 '26 |
Proposed Sale |
22.16 |
150,000 |
3,324,060 |
0 |
大文字化:
|
ボリューム (24 時間):